| Autor: |
Deodhar, Atul, Gottlieb, Alice B, Boehncke, Wolf-Henning, Dong, Bin, Wang, Yuhua, Zhuang, Yanli, Barchuk, William, Xu, Xie L, Hsia, Elizabeth C, AELION, Jacob, AMARELO-RAMOS, Juan, BALSA, Alejandro, BERGHEA, Florian, BRZEZICKI, Jan, BURNETTE, Michael, FRETZIN, Scott, GARCÍA-CARAZO, Sara, GLADSTEIN, Geoffrey, GOMEZ-REINO, Juan, GOODERHAM, Melinda, GONZÁLEZ-FERNÁNDEZ, Carlos, GOTTLIEB, Alice, GRATACOS, Jordi, HAALAND, Derek, KAMALOVA, Rima, LESZCZYNSKI, Piotr, MARTIN-MOLA, Emilio, MASLYANSKY, Alexey, NAVARRO, Federico, OPRIS, Daniela, PAPP, Kim, PERLAMUTROV, Yuriy, PHILIPP, Sandra, RACEWICZ, Artur, REBROV, Andrey, RELL-BAKALARSKA, Maria, ROSMARIN, David, RUBBERT-ROTH, Andrea, SHERGY, William, SHIRINSKY, Ivan, SONIN, Dmitry, STANISLAV, Marina, SUKHAREV, Alexey, TEMNIKOV, Vadim, VINOGRADOVA, Irina, WAYTZ, Paul, YAKUSHEVICH, Vladimir |
| Zdroj: |
The Lancet; June 2018, Vol. 391 Issue: 10136 p2213-2224, 12p |
| Abstrakt: |
Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
